Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results
-
- Srdan Verstovsek
- Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX;
-
- Francesco Passamonti
- Department of Medicine and Surgery, University of Insubria, Varese, Italy;
-
- Alessandro Rambaldi
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXII, Bergamo, Italy;
-
- Giovanni Barosi
- Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Foundation, Pavia, Italy;
-
- Elisa Rumi
- Department of Molecular Medicine, University of Pavia, Pavia, Italy;
-
- Elisabetta Gattoni
- Department of Oncology, Ospedale Santo Spirito, Casale Monferrato, Italy;
-
- Lisa Pieri
- Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;
-
- Huiling Zhen
- Incyte Corporation, Wilmington, DE; and
-
- Muriel Granier
- Incyte Corporation, Wilmington, DE; and
-
- Albert Assad
- Incyte Corporation, Wilmington, DE; and
-
- Mario Cazzola
- Department of Molecular Medicine, University of Pavia, Pavia, Italy;
-
- Hagop M. Kantarjian
- Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX;
-
- Tiziano Barbui
- Clinical Research Foundation (FROM), Ospedale Papa Giovanni XXIII, Bergamo, Italy
-
- Alessandro M. Vannucchi
- Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;
収録刊行物
-
- Blood
-
Blood 130 (15), 1768-1771, 2017-10-12
American Society of Hematology